Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors

Journal of Medicinal Chemistry

Volumn 50, Issue 7, 2007, Pages 1514-1527

  Tao, Zhi Fu ^a   Wang, Le ^a   Stewart, Kent D ^a   Chen, Zehan ^a   Gu, Wendy ^a   Bui, Mai Ha ^a   Merta, Philip ^a   Zhang, Haiying ^a   Kovar, Peter ^a   Johnson, Eric ^a   Park, Chang ^a   Judge, Russell ^a   Rosenberg, Saul ^a   Sowin, Thomas ^a   Lin, Nan Horng ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 1 INHIBITOR; DOXORUBICIN; MACROCYCLIC COMPOUND; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CRYSTALLOGRAPHY; CULTURE MEDIUM; CYCLIZATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; GRUBBS METATHESIS MACROCYCLIZATION; HELA CELL; HUMAN; HUMAN CELL; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DNA DAMAGE; DOXORUBICIN; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; MACROCYCLIC COMPOUNDS; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 34147108049     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061247v     Document Type: Article

References (61)

1. Hurley, L. H. DNA and its associated processes as targets for cancer therapy. Nat. Rev. Cancer 2002, 2, 188-200.
2. Sancar, A.; Lindsey-Boltz, L. A.; Unsal-Kacmaz, K.; Linn, S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 2004, 73, 39-85.
3. Zhou, B.-B.; Bartek, J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat. Rev. Cancer 2004, 4, 216-255.
4. Kastan, M. B.; Bartek, J. Cell-cycle checkpoints and cancer. Nature 2004, 432, 316-323.
5. Walwroth, N.; Davery, S.; Beach, D. Fission yeast Chk1 protein kinase links the rad checkpoint pathway to cdc2. Nature 1993, 363, 368-371.
6. Chen, Y.; Sanchez, Y. Chk1 in the DNA damage response: conserved roles from yeasts to mammals. DNA Repair 2004, 3, 1025-1032.
7. 2/M DNA damage checkpoint. Genes Dev. 2000, 14, 1448-1459.
8. Zhao, H.; Piwnica-Worms, H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol. Cell. Biol. 2001, 21, 4129-4139.
9. Gatei, M.; Sloper, K.; Sörensen, C.; Syljuäsen, R.; Falck, J.; Hobson, K.; Savage, K.; Lukas, J.; Zhou, B.; Bartek, J.; Khanna, K. K. Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J. Biol. Chem. 2003, 278, 14806-14811.
10. Yarden, R. O.; Pardon-Reoyo, S.; Sgagias, M.; Cowan, K. H.; Body, L. C. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat. Genet. 2002, 30, 285-289.
11. (a) Wang, H.; Wang, X.; Zhou, X.-Yang.; Chen, D. J.; Li, G. C.; Iliakis, G.; Wang, Y. Ku affects the ataxia and rad 3-related/CHK1-dependent S phase checkpoint response after camptothecin treatment. Cancer Res. 2002, 62, 2483-2487.
12. 2 arrests through Cdc25A degradation in response to DNA-damaging agents. J. Biol. Chem. 2003, 278, 21767-21773.
13. Koniaras, K.; Cuddihy, A. R.; Christopoulos, H.; Hogg, A.; O'Connell, M. J. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 2001, 20, 7453-7463.
14. Zachos, G.; Rainey, M. D.; Gillespie, D. A. Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects. EMBO J. 2003, 22, 713-723.
15. Xiao, Z.; Xue, J.; Sowin, T. J.; Rosenberg, S.; Zhang, H. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene 2005, 24, 1403-1411.
16. Prudhomme, M. Combining DNA damaging agents and checkpoint 1 inhibitors. Curr. Med. Chem.: Anti-Cancer Agents 2004, 4, 435-438.
17. Kong, N.; Fotouhi, N.; Wovkulich, P. M.; Roberts, J. Cell cycle inhibitors for the treatment of cancer. Drugs Future 2003, 28, 881-896.
18. 2 checkpoint abrogators as anticancer drugs. Mol. Cancer Ther. 2004, 3, 513-519.
19. For recent reviews on Chk1 inhibitors, see (a) Tao, Z.-F.; Lin, N.-H. Chk1 inhibitors for novel cancer treatment. Anti-cancer Agents Med. Chem. 2006, 6, 377-388.
20. (b) Prudhomme, M. Novel checkpoint 1 inhibitors. Recent Pat. Anti-Cancer Drug Discovery 2006, 1, 55-68.
21. Graves, P. R.; Yu, L.; Schwarz, J. K.; Gales, J.; Sausville, E. A.; O'Connor, P. M.; Piwnica-Worms, H. The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01. J. Biol. Chem. 2000, 275, 5600-5605.
22. 2 DNA damage checkpoint inhibitor isogranulatimide. Mol. Cancer Ther. 2004, 3, 1221-1227.
23. 2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine. J. Biol. Chem. 2001, 276, 17914-17919.
24. Lyne, P. D.; Kenny, P. W.; Cosgrove, D. A.; Deng, C.; Zabludoff, S.; Ashwell, S.; Wendoloski, J. J. Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. J. Med. Chem. 2004, 47, 1962-1968.
25. Foloppe, N.; Fisher, L. M.; Howes, R.; Kierstan, P.; Potter, A.; Robertson, A. G. S.; Surgenor, A. E. Structure-Based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand Affinity. J. Med. Chem. 2005, 48, 4332-4345.
26. Lin, N.-H.; Xia, P.; Kovar, P.; Park, C.; Chen, Z.; Zhang, H.; Rosenberg, S. H.; Sham, H. L. Synthesis and biological evaluation of 3-ethylidene-1,3- dihydro-indol-2-ones as novel checkpoint 1 inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 421-426.
27. Ni, Z.-J.; Barsanti, P.; Brammeier, N.; Diebes, A.; Poon, D. J.; Ng, S.; Pecchi, S.; Pfister, K.; Renhowe, P. A.; Ramurthy, S.; Wagman, A. S.; Bussiere, D. E.; Le, V.; Zhou, Y.; Jansen, J. M.; Ma, S.; Gesner, T. G. 4-(Aminoalkylamino)-3-benzimidazole-quinolinones as potent Chk-1 inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 3121-3124.
28. (a) Shao, R. G.; Cao, C. X.; Shimizu, T.; O'Connor, P. M.; Kohn, K. W.; Pommier, Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res. 1997, 57, 4029-4035.
29. (b) Shi, Z.; Azuma, A.; Sampath, D. S-Phase Arrest by Nucleoside Analogues and Abrogation of Survival without Cell Cycle Progression by 7-Hydroxystaurosporine. Cancer Res. 2001, 61, 1065.
30. (c) Bunch, R. T.; Eastman, A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin. Cancer Res. 1996, 2, 791-797.
31. (d) Busby, E. C.; Leistritz, D. F.; Abraham, R. T.; Karnitz, L. M.; Sarkaria, J. N. The Radiosensitizing Agent 7-Hydroxystaurosporine (UCN-01) Inhibits the DNA Damage Checkpoint Kinase Chk1. Cancer Res. 2000, 60, 2108.
32. (e) Hsueh, C.; Kelsen, D.; Schwartz, G. K. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner. Clin. Cancer Res. 1998, 4, 2201-2206.
33. (f) Wang, Q.; Fan, S.; Eastman, A.; Worland, P. J.; Sausville, E. A.; O'Connor, P. M. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst. (Bethesda) 1996, 88, 956-965.
34. (g) Tse, A. N.; Schwartz, G. K. Potentiation of cytotoxicity of topoisomerase I poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Cancer Res. 2004, 64, 6635-6644.
35. Fuse, E.; Tanii, H.; Kurata, N.; Kobayashi, H.; Shimada, Y.; Tamura, T.; Sasaki, Y.; Tanigawara, Y.; Lush, R. D.; Headlee, D.; Figg, W. D.; Arbuck, S. G.; Senderowicz, A. M.; Sausville, E. A.; Akinaga, S.; Kuwabara, T.; Kobayashi, S. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res. 1998, 58, 3248-3253.
36. Chen, Z.; Xiao, Z.; Gu, W.-Z.; Xue, J.; Bui, M.; Kovar, P.; Li, G.; Wang, G.; Tao, Z.-F.; Tong, Y.; Lin, N.-H.; Sham, H. L.; Wang, J. Y.; Sowin, T. J.; Rosenberg, S. H.; Zhang, H. Y. Selective Chk1 inhibitors differentially sensitize a broad range of p53-deficient cancer cells to cancer therapeutics. Int. J. Cancer 2006, 119, 2784-2794.
37. Wang, G. T.; Li, G.; Mantei, R. A.; Chen, Z.; Kovar, P.; Gu, W.; Xiao, Z.; Zhang, H.; Sham, H. L.; Sowin, T.; Rosenberg, S. H.; Lin, N.-H. 1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyano-pyrazi-2-yl)ureas as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities. J. Med. Chem. 2005, 48, 3118-3121.
38. (a) Dumas, J.; Smith, R. A.; Lowinger, T. B. Recent developments in the discovery of protein kinase inhibitors from the urea class. Curr. Opin. Drug Discovery Dev. 2004, 7, 600-616.
39. (b) Dumas, J. Protein kinase inhibitors from the urea class. Curr. Opin. Drug Discovery Dev. 2002, 5, 718-727.
40. Keegan, K.; Kesicki, E. A.; Gaudino, J. J.; Cook, A. W.; Cowen, S. D.; Gurgess, L. E. Aryl and heteroaryl urea Chk1 inhibitors for use as radiosensitizers and chemosensitizers. WO 2002070494, 2002.
41. Boyle, R. G.; Imogal, H. J.; Cherry, M. Diarylurea compounds and derivatives as Chk1 inhibitors for the treatment of cancer. WO 2003101444, 2003.
42. Boyle, R. G.; Imogal, H. J.; Cherry, M. Khan, N. M. Diarylurea compounds as Chk1 inhibitors. WO 2005072733, 2005.
43. Li, Q.; Li, T.; Lin, N.-H.; Mantei, R. A.; Sham, H. L.; Wang, G. T. Urea kinase inhibitors, U.S. Patent 2004034038, 2004.
44. Tao, Z.-F.; Lin, N.-H.; Wang, L.; Sowin, T. J. Macrocyclic kinase inhibitors. U.S. Patent 20050215556, 2005.
45. Tao, Z.-F.; Lin, N.-H.; Wang, L.; Sowin, T. J.; Sullivan, G. M.; Tong, Y.; Przytulinska, M.; Li, G. Macrocyclic kinase inhibitors. WO 2005047294, 2005.
46. Tao, Z.-F.; Li, G.; Wang, G. T.; Kovar, P.; Zhang, H.; Park, C.; Stewart, K.; Sham, H. L.; Sowin, T.; Rosenberg, S. H.; Lin, N.-H. Pyrazyl phenyl ureas as potent and selective Chk 1 inhibitors: the exploration of C6′-position of pyrazyl ring and SAR studies at C4-position of phenyl ring. 229th ACS National Meeting, San Diego, CA, March 13-17, 2005; MEDI-145.
47. Li, G.; Hasvold, L. A.; Tao, Z.-F.; Wang, G. T.; Gwaltney, S. L., II; Patel, J.; Kovar, P.; Credo, R. B.; Chen, Z.; Zhang, H.; Park, C.; Sham, H. L.; Sowin, T.; Rosenberg, S. H.; Lin, N. H. Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 2293-2298.
48. (a) For a review: Chen, X.; Wang, W. The use of bioisosteric groups in lead optimization. Annu. Rep. Med. Chem. 2003, 38, 333-346.
49. (b) Dinsmore, C. J.; Bogusky, M. J.; Culberson, J. C.; Bergman, J. M.; Homnick, C. F.; Zartman, C. F.; Mosser, S. D.; Schaber, M. D.; Robinson, R. G.; Koblan, K. S.; Huber, H. E.; Graham, S. L.; Hartman, G. D.; Huff, J. R.; Williams, T. M. Conformational restriction of flexible ligands guided by the transferred NOE experiment: potent macrocyclic inhibitors of farnesyltransferase. J. Am. Soc. Chem. 2001, 123, 2107-2108.
50. (c) Chen, K. X.; Njoroge, F. G.; Pichardo, J.; Prongay, A.; Butkiewicz, N.; Yao, N.; Madison, V.; Girijavallabhan, V. Design, synthesis, and biological activity of m-tyrosine-based 16- and 17-membered macrocyclic inhibitors of hepatitis C virus NS3 serine protease. J. Med. Chem. 2005, 48, 6229-6235.
51. (d) Chen, K. X.; Njoroge, F. G.; Pichardo, J.; Prongay, A.; Butkiewicz, N.; Yao, N.; Madison, V.; Girijavallabhan, V. Potent 7-hydroxy-1,2,3,4- tetrahydroisoquinoline-3-carboxylic acid-based macrocyclic inhibitors of hepatitis C virus NS3 protease. J. Med. Chem. 2006, 49, 567-574.
52. (e) Chen, K. X.; Njoroge, F. G.; Arasappan, A.; Venkatraman, S.; Vibulbhan, B.; Yang, W.; Parekh, T. N.; Pichardo, J.; Prongay, A.; Cheng, K.-C.; Butkiewicz, N.; Yao, N.; Madison, V.; Girijavallabhan, V. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles. J. Med. Chem. 2006, 49, 995-1005.
53. Verardo, G.; Giumanini, A. G.; Strazzolini, P. Poiana, M. Reductive N-monoalkylation of primary aromatic amines. Synthesis 1993, 121-125.
54. Dai, W.-M.; Guo, D.-S.; Sun, L.-P. Chemistry of aminophenols. Part 1: Remarkable additive effect on Sonogashira cross-coupling of 2-carboxamidoaryl triflates and application to novel synthesis of indoles. Tetrahedron Lett. 2001, 42, 5275-5278.
55. 4 oxidation of olefins to cis-1,2-glycols using tertiary amine oxides as the oxidant. Tetrahedron Lett. 1976, 17, 1973-1976.
56. Foloppe, N.; Fisher, L. M.; Francis, G.; Howes, R.; Kierstan, P.; Potter, A. Identification of a buried pocket for potent and selective inhibition of Chk1: Prediction and verification. Bioorg. Med. Chem. 2006, 14, 1792-1804.
57. (a) Squire, C. J.; Dickson, J. M.; Ivanovic, I.; Baker, E. N. Structure and inhibition of the human cell cycle checkpoint kinase, Wee1A kinase: An atypical tyrosine kinase with a key role in CDK1 regulation. Structure 2005, 13, 541-550.
58. (b) Palmer, B. D.; Thompson, A. M.; Booth, R. J.; Dobrusin, E. M.; Kraker, A. J.; Lee, H. H.; Lunney, E. A.; Mitchell, L. H.; Ortwine, D. F.; Smaill, J. B.; Swan, L. M.; Denny, W. A. 4-Phenylpyrrolo[3,4-c]carbazole- 1,3-(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution. J. Med. Chem. 2006, 49, 4896-4911.
59. Knight, Z. A.; Shokat, K. M. Features of selective kinase inhibitors. Chem. Biol. 2005, 12, 621-637.
60. Thomas, C. J.; Rahier, N. J.; Hecht, S. M. Camptothecin: current perspectives. Bioorg. Med. Chem. 2004, 12, 1585-1604.
61. Chen, Z.; Xiao, Z.; Chen, J.; Ng, S. C.; Sowin, T. J.; Sham, H.; Rosenberg, S.; Fesik, S.; Zhang, H. Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Mol. Cancer Ther. 2003, 2, 543-8.